

We're pleased to announce our

HTAi
PATIENT AND
CITIZEN
INVOLVEMENT
STEWARDSHIP GROUP

Co-Chairs
Aline Silva
Patient Voices Network, Canada & Research Manager &
Executive Director of Public Engagement, University of Alberta

Fiona Pearce
Senior Advisor, HTAi & Consumer Engagement & Education,
Interim Head CEE, Agency for Care Effectiveness, Ministry of
Health, Singapore

Vice Chair
Zal Press
Chief-Char, CADTH Patient & Community Advisory Committee,
Toronto, Canada

+ New Steering Committee member
Catherine Koola
Associate Director of Patient Engagement, Institute for Clinical
and Economic Research (ICER) USA


SHARING ACE'S PATIENT INVOLVEMENT INITIATIVES

The CEE team was invited to speak at two local events during the last few months on opportunities for patients to be involved in HTA. The team showcased the collaborative efforts between ACE and patient organisations, highlighting the contributions patients have made to ACE's work and healthcare-decision making in Singapore.

1. 11th Annual Inflammatory Bowel Disease (IBD) Patient Education & Public Awareness Seminar, Crohn's and Colitis Society of Singapore, 20 May 2023



2. SingHealth Patient Advocacy Network (SPAN) members' meeting, 25 July 2023






Annual call for topics

Each year, usually from October to January, clinicians from public healthcare institutions are invited to suggest which drugs or medical devices they would like ACE to evaluate for different conditions during the **annual call for topics**. This process ensures that the health technologies chosen for evaluation address priority issues which will help improve the health of the population.

From **October 2023**, patients, carers and patient organisations will also now be invited to suggest which health technologies they would like ACE to evaluate. All patient organisations will receive an application form from the CEE team. Stay tuned for more details!

PATIENT GLOSSARY

[FIND OUT MORE](#)



What is cost-effectiveness?

What is health technology assessment?

What is an outcome?

ACE's **patient glossary** has been developed by the CEE team to provide patients and their carers with simple definitions of technical terms that are often used in ACE's health technology assessments.

5 NEW PLAIN ENGLISH SUMMARIES PUBLISHED SINCE JUNE 2023

**FIND OUT
MORE**

Plain English summaries (PES) provide brief information about the treatments and conditions that have been evaluated by ACE and describe the key funding recommendations made by the MOH Drug Advisory Committee.

Newly published PES:

- Anabolic drugs for treating osteoporosis
- Botulinum toxin A for treating adults with focal spasticity of the lower limbs associated with stroke
- Ixekizumab and secukinumab for treating non-radiographic axial spondyloarthritis
- Trastuzumab deruxtecan for previously treated HER2-positive advanced gastric cancer
- Trastuzumab deruxtecan for previously treated HER2-positive metastatic breast cancer



3 PATIENT FACTSHEETS PUBLISHED SINCE JUNE 2023


**FIND OUT
MORE**

Patient factsheets are co-developed with patient organisations and clinicians to equip patients with helpful and evidence-based information on different medical conditions and policies, and encourage shared decision-making with their doctors about their healthcare needs. Patients are invited to comment on the factsheets during their development to ensure they are relevant and useful.

Links to relevant patient organisations are also included in the factsheets for interested readers to seek more information on peer support.

New factsheets:

- Injectable treatments for type 2 diabetes
- SSRIs for depression
- Treatments for HIV infection



We would like to thank members from the patient organisations for providing feedback and suggestions to help inform the content and layout of these new factsheets.

30 PATIENT RESPONSES ABOUT
ACE'S DRUG EVALUATIONS
WERE GATHERED FROM

9 PATIENT ORGANISATIONS FOR

5 TOPICS PRESENTED TO THE MOH DRUG
ADVISORY COMMITTEE IN JUNE 2023



Patients and carers were invited to provide their lived experiences about medical conditions, treatments and unmet needs to inform ACE's technical evaluations. A big thank you to the patient organisations that helped to gather input from their members! The insights received were very helpful to inform the MOH Drug Advisory Committee's (DAC) funding recommendations.

The CEE team notifies patient organisations of the DAC's funding recommendations after each meeting and provides feedback on which information provided by patients was most helpful to inform the DAC's deliberations. The CEE team also invites suggestions on how the patient involvement processes can improve.



A new factsheet which provides a visual reference of the **patient input process** is now available! This factsheet summarises the key steps for patients and carers who would like to provide input to inform ACE's technical evaluations. Click on the image on the left to view the factsheet.

For the latest updates on the *Process and methods guide for patient involvement* and related educational resources, visit ACE's **Opportunities for Patient Involvement** page.

**FIND OUT
MORE**

About CEE

The Consumer Engagement and Education (CEE) team supports patient involvement in ACE's work and co-develops plain English summaries and educational resources with patient organisations to improve health literacy and encourage shared healthcare decision-making between patients and their doctors.

Tell us what matters to you, your organisation or your community. Email us at ACE_CEE@moh.gov.sg.

The Agency for Care Effectiveness (ACE) was established by the Ministry of Health (Singapore) to drive better decision-making in healthcare through health technology assessment (HTA), clinical guidance and education. © Agency for Care Effectiveness, Ministry of Health, Republic of Singapore.

Published on 11 August 2023. To find out more about ACE, scan the QR code or visit www.ace-hta.gov.sg. You can also follow us on social media at:

